Ainos (AIMD) risk factors, FY2024 10-K

Risks related to our limited operating history, financial position, and need for additional capital

1. 01We have a history of operating losses that are expected to continue for the foreseeable future, and we are unable to predict the extent of future losses, or whether we will generate significant revenues or achieve or sustain profitability
2. 02We have generated very little revenue from product sales and may never become profitable
3. 03We need to raise additional capital to operate our business. If we fail to obtain the capital necessary to fund our operations, we will be unable to continue or complete our product development
4. 04We may be unable to access the capital markets and even if we can raise additional funding, we may be required to do so on terms that are dilutive to you
5. 05Our operating results may fluctuate significantly, which will make our future results difficult to predict and could cause our results to fall below expectations

Risks related to product development and regulatory process

1. 06Any of these occurrences may harm our business, financial condition and prospects significantly. Delays in clinical product development present material uncertainty and risk with respect to our clinical trials, business, and financial condition
2. 07Our long-term prospects depend in part upon discovering, developing and commercializing additional products, including POCT and VELDONA candidates, which may fail in development or suffer delays that adversely affect their commercial viability
3. 08Even if a current or future product candidate, including POCT and VELDONA, receives marketing approval, it may fail to achieve the degree of market acceptance by physicians, patients, third-party payors and others in the medical community necessary for commercial success
4. 09The total addressable market opportunity for our current and future products may be much smaller than we estimate
5. 10We may not obtain approval for our product candidates in any jurisdictions
6. 11Even if we are able to commercialize any product candidates, such products may become subject to unfavorable pricing regulations or third-party coverage and reimbursement policies, which would harm our business
7. 12If product liability lawsuits are brought against us, we may incur substantial liabilities and may be required to limit commercialization of any approved products
8. 13Our inability to obtain sufficient product liability insurance at an acceptable cost or at all to protect against potential product liability claims could prevent or inhibit the commercialization of products we develop, alone or with collaboration partners
9. 14Any disruption in our research and development facility could adversely affect our business, financial condition and results of operations
10. 15Our business and operations would be adversely affected in the event that our computer systems or those of our partners, contract research organizations, contractors, consultants or other third parties we work with were to suffer system failures, cyber-attacks, loss of data or other security incidents

Risks related to reliance on third parties

1. 16We do not own or operate manufacturing facilities. Our current strategy is to outsource all manufacturing of our product and product candidates to other companies, including TCNT, our affiliate and product co-developer, and Swiss Pharmaceutical Co., Ltd
2. 17If we engage additional manufacturers in the future, our use of new manufacturers increases the risk of delays in production or insufficient supplies of our product candidates
3. 18We may be delayed if we need to change the manufacturing process used by our manufacturers. Further, if we change an approved manufacturing process, then we may be delayed if the FDA or a comparable foreign authority needs to review the new manufacturing process before it may be used
4. 19Our future product candidates and any products that we may develop may compete with other product candidates and products for access to manufacturing facilities
5. 20We currently have limited marketing capabilities. If we are unable to expand sales and marketing capabilities on our own or through third parties, or are delayed in establishing these capabilities, we will be unable to successfully commercialize our product candidates, if approved, or generate product revenue
6. 21We may form or seek strategic partnerships in the future, and we may not realize the benefits of such alliances or licensing arrangements

Risks related to intellectual property, patents, and data privacy

1. 22Intellectual property rights vary across foreign jurisdictions, and we may not be able to protect our intellectual property rights throughout the world
2. 23We may become involved in lawsuits to protect or enforce our patents or other intellectual property, which could be expensive, time-consuming and unsuccessful, and issued patents directed towards our technology and product candidates could be found invalid or unenforceable if challenged
3. 24Patent terms may be inadequate to protect our competitive position on our product candidates for an adequate amount of time
4. 25If we are unable to protect the confidentiality of our trade secrets, our business and competitive position could be harmed
5. 26We may be subject to damages resulting from claims that we or our employees have wrongfully used or disclosed alleged trade secrets of our competitors or are in breach of non-competition or non-solicitation agreements with our competitors
6. 27Changes in U.S. patent law, or laws in other countries, could diminish the value of patents in general, thereby impairing our ability to protect our product candidates

Risks related to our business

1. 28We will need to increase the size of our Company and may not effectively manage our growth
2. 29Our future success depends on our ability to retain key executives and to attract, retain and motivate qualified personnel
3. 30As we are actively involved in marketing VELDONA Pet supplements within a fiercely competitive industry, any inability to effectively compete may adversely impact our operational results
4. 31The point-of-care testing (“POCT”) market is extremely competitive and rapidly evolving, making it difficult to evaluate our business and future prospects
5. 32We will be required to continuously enhance our products and develop new tests to keep pace with evolving standards of care. If we do not update our products to keep pace with technological and scientific advances, our products could become obsolete and sales of our products could decline or fail to grow as expected
6. 33Research and development of drug candidates as VELDONA is extremely expensive and complex and its difficult to evaluate the likelihood of the outcome of clinical trials, regulatory approvals, and our business and future prospects
7. 34If we fail to develop and maintain our brand, or the quality of our products that customers have come to expect, our business could suffer
8. 35Our business, operations, clinical development plans and timelines, and supply chain could be adversely affected by the effects of epidemics, including but not limited to COVID-19
9. 36Our common stock and public warrants are currently quoted on the Nasdaq Capital Market
10. 37We do not intend to pay dividends for the foreseeable future and, as a result, our ability to achieve a return on your investment will depend on appreciation in the price of our common stock
11. 38Any failure to maintain effective internal control over financial reporting could harm us
12. 39Our issuance of additional capital stock in connection with financings, acquisitions, investments, our 2023 Stock Incentive Plan or otherwise will dilute all other stockholders